Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial -A Prospective Randomized Study

다국어 초록 (Multilingual Abstract)

Background and Objectives: We investigate to determine whether N-acetylcysteine (NAC) can prevent anthracycline-induced cardiotoxicity.
Subjects and Methods: A total of 103 patients were enrolled in this prospective randomized open label controlled trial. They are patients first diagnosed with breast cancer or lymphoma, who require chemotherapy, including anthracycline like adriamycine or epirubicine. Pa-tients were randomized to the NAC group {n=50; 1200 mg orally every 8 hours starting before and ending after the intravenous infusion of anthracycline in all chemotherapy cycles (3-6)} or the control group (n=53). Primary outcome was the decrease in left ventricular ejection fraction (LVEF) absolutely ≥10% from the baseline and concomitantly <50% at 6-month. Composite of all-cause death, heart failure and re-admission were compared.
Results: The primary outcome was not significantly different in the NAC and control groups {3/47 (6.4%) vs. 1/52 (1.9%), p=0.343}. The mean LVEF significantly decreased in both the NAC (from 64.5 to 60.8%, p=0.001) and control groups (from 64.1 to 61.3%, p<0.001) after the completion of whole chemotherapy. The mean LVEF change did not differ between the two groups (-3.64% in NAC vs. -2.78% in control group, p=0.502). Left ventricular (LV) end systolic dimension increased with higher trend in NAC by 3.08±4.56 mm as compared with 1.47±1.83 mm in the control group (p=0.064). LV end diastolic dimension did not change in each group and change does not differ in both. Peak E, A and E/A ratio change and cardiac enzymes were comparable in two groups. Cumulative 12-month event rate was 6% and 3.8% in the NAC group and the control group, respectively, with no difference (p=0.672).
Conclusion: We cannot prove that NAC prevents anthracycline-induced cardiomyopathy.

참고문헌 (Reference)

1 Li K, "Thrombopoietin protects against in vitroand in vivo cardiotoxicity induced by doxorubicin" 113 : 2211-2220, 2006

2 Fallah-Rad N, "The utility of cardiac biomarkers,tissue velocity and strain imaging, and cardiac magnetic resonanceimaging in predicting early left ventricular dysfunction in patients withhuman epidermal growth factor receptor II-positive breast cancertreated with adjuvant trastuzumab therapy" 57 : 2263-2270, 2011

3 Hong HJ, "Tanshinone IIAprevents doxorubicin-induced cardiomyocyte apoptosis through Aktdependentpathway" 157 : 174-179, 2012

4 Hequet O, "Subclinical late cardiomyopathy afterdoxorubicin therapy for lymphoma in adults" 22 : 1864-1871, 2004

5 Kalay N, "Protective effects of carvedilol againstanthracycline-induced cardiomyopathy" 48 : 2258-2262, 2006

6 Cardinale D, "Prognostic value of troponin Iin cardiac risk stratification of cancer patients undergoing high-dosechemotherapy" 109 : 2749-2754, 2004

7 Li L, "Preventive effect of erythropoietin on cardiacdysfunction in doxorubicin-induced cardiomyopathy" 113 : 535-543, 2006

8 Tepel M, "Prevention of radiographic-contrast-agent-induced reductions in renalfunction by acetylcysteine" 343 : 180-184, 2000

9 Cardinale D, "Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition" 114 : 2474-2481, 2006

10 Doroshow JH, "Prevention of doxorubicincardiac toxicity in the mouse by N-acetylcysteine" 68 : 1053-1064, 1981

11 Urbanova D, "Natriuretic peptides: biochemicalmarkers of anthracycline cardiac toxicity?" 17 : 51-58, 2008

12 Lee CY, "Natriuretic peptides and therapeutic applications" 12 : 131-142, 2007

13 Spallarossa P, "Matrix metalloproteinase-2and -9 are induced differently by doxorubicin in H9c2 cells: The role ofMAP kinases and NAD(P)H oxidase" 69 : 736-745, 2006

14 Chao HH, "L-carnitine reducesdoxorubicin-induced apoptosis through a prostacyclin-mediatedpathway in neonatal rat cardiomyocytes" 146 : 145-152, 2011

15 Neilan TG, "Iloprost attenuates doxorubicininducedcardiac injury in a murine model without compromising tumoursuppression" 27 : 1251-1256, 2006

16 Deng S, "Gp91phox-containing NAD(P)H oxidase increases superoxide formationby doxorubicin and NADPH" 42 : 466-473, 2007

17 Lipshultz SE, "Female sex and drug dose asrisk factors for late cardiotoxic effects of doxorubicin therapy for childhoodcancer" 332 : 1738-1743, 1995

18 Takemura G, "Doxorubicin-induced cardiomyopathy fromthe cardiotoxic mechanisms to management" 49 : 330-352, 2007

19 Swain SM, "Congestive heart failure in patientstreated with doxorubicin: a retrospective analysis of three trials" 97 : 2869-2879, 2003

20 Bristow MR, "Clinical spectrum ofanthracycline antibiotic cardiotoxicity" 62 : 873-879, 1978

21 Figueredo VM, "Chemical cardiomyopathies: the negative effects ofmedications and nonprescribed drugs on the heart" 124 : 480-488, 2011

22 Yeh ET, "Cardiovascular complications of cancertherapy: diagnosis, pathogenesis, and management" 109 : 3122-3131, 2004

23 Pai VB, "Cardiotoxicity of chemotherapeutic agents: incidence,treatment and prevention" 22 : 263-302, 2000

24 Feola M, "Cardiotoxicity after anthracyclinechemotherapy in breast carcinoma: effects on left ventricular ejectionfraction, troponin I and brain natriuretic peptide" 148 : 194-198, 2011

25 Steinherz LJ, "Cardiac toxicity4 to 20 years after completing anthracycline therapy" 266 : 1672-1677, 1991

26 Zucchi R, "Cardiac toxicity of antineoplastic anthracyclines" 3 : 151-171, 2003

27 Rosenthal DS, "Cardiac effects of radiation therapy andchemotherapy, In Heart Disease: A Textbook ofCardiovascular Medicine" WB Saunders Co. 1746-1751, 2001